Entera Bio Ltd has been focusing on its Phase 2 clinical trial involving EB613, and it is impressed with the progress so far. The company exudes confidence that EB613 will be effective in the treatment of patients struggling with osteoporosis. Entera pulls along as the first oral bone-building product to be used in the treatment of osteoporosis.
Conducting tests
The company wants to test the substance’s safety, and it will conduct the experiments in Israel. It has already identified some top medical centers in which it will test the EB613 efficacy. The business also looks forward to discovering some trusted doses to be used in the potential Phase 3 registration trial.
The company has been checking out the trial’s complete 3-month biomarker data and is quite pleased by the outcome. Entera is quite impressed about the trial has met the primary endpoint. The unveiling of the complete 3-month results indicated a major rise in the P1NP biomarker, and that was in a test done alongside a placebo. P1NP can be described as a biomarker with the capacity to show the rate of new bone formation.
The secondary endpoints highlighted treatment effects on several serum bone biomarkers such as CTX and Osteocalcin.
Jamas speaks out on recent developments
Entera CEO Spiros Jamas discloses that they will soon unveil the final results. According to him, the interested parties will take a look at the second quarter’s BMD data.
Jamas believes that the data in question will be useful for the business development discussions they will undertake with their partners. The official was speaking in relation o the various partners with a deep interest in osteoporosis.
Experts checking out the reported data see it as a showcasing of Entera’s drug delivery platform’s power in oral dosing of enormous biological molecules.
Osteoporosis continues to be one of the most deadline health conditions globally, and it causes the deterioration of bone tissues within the human body. Research also shows how the bone mass decreases among the affected persons. Affected persons become more vulnerable to fractures, but Entera wants to change matters by providing trusted solutions.
